A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Key facts

Study ID

NCT06859268

Run by

Eli Lilly and Company

People needed

643

Starts

2025-03-05

Expected to finish

2028-04-01

Last updated by the study team

2026-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight

You may not qualify if…

• Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening
• Have a prior or planned surgical treatment for obesity
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity
• Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• Have had within the past 90 days before screening:
• acute myocardial infarction
• cerebrovascular accident (stroke)
• hospitalization for unstable angina, or
• hospitalization due to congestive heart failure
• Have New York Heart Association Functional Classification Class IV congestive heart failure
• Have a history of chronic or acute pancreatitis
• Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States
• CMR of Greater New Haven, LLC — Hamden, Connecticut, United States
• ALL Medical Research, LLC — Cooper City, Florida, United States
• Florida International Medical Research — Coral Gables, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Charter Research - Winter Park — Orlando, Florida, United States
• Metabolic Research Institute, Inc. — West Palm Beach, Florida, United States
• Kubost Clinical Research - Marietta — Marietta, Georgia, United States
• North Georgia Clinical Research — Woodstock, Georgia, United States
• Pacific Diabetes & Endocrine Center — Honolulu, Hawaii, United States
• Alliance for Multispecialty Research, LLC — Oak Brook, Illinois, United States
• Springfield Clinic Main Campus — Springfield, Illinois, United States
• Alliance for Multispecialty Research, LLC — Lexington, Kentucky, United States
• L-MARC Research Center — Louisville, Kentucky, United States
• Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States
• Care Access - Lake Charles (Bayou Pines) — Lake Charles, Louisiana, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Alliance for Multispecialty Research, LLC — Kansas City, Missouri, United States
• Vector Clinical Trials — Las Vegas, Nevada, United States
• Dent Neurosciences Research Center, Inc — Amherst, New York, United States
• Carteret Medical Group — Morehead City, North Carolina, United States
• Care Access - Raleigh — Raleigh, North Carolina, United States
• Tekton Research, LLC. — Moore, Oklahoma, United States
• Altoona Center For Clinical Research — Duncansville, Pennsylvania, United States
• Southern California Clinical Research — Santa Ana, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.